Drug Trial Radar · NCT00074724
Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
319
Actual
Start
May 2003
Primary completion
Dec 2008
Study completion Apr 2017
Sponsor
- Lead sponsor
- Medstar Health Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Dec 23, 2003
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To define the role of the assessment of myocardial viability with dobutamine echocardiography (DE) in the clinical evaluation and selection of the best treatment for a high-risk subset of patients with coronary artery disease.
Conditions
- Cardiovascular Diseases
- Coronary Disease
- Heart Failure
- Heart Failure, Congestive
- Heart Diseases
Interventions
Coronary Artery BypassProcedure
coronary revascularization using arterial or vein conduits
Modern medical managementDrug
Therapies with evidence-based recommendations.
Dobutamine echocardiographyDevice
Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
Optimal medical therapyDrug
All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival Free of Cardiac HospitalizationTime frame: 3 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.